Catalyst Wire Dossier Catalyst Wire Dossier

SPESOLIMAB

BI655130 · Boehringer Ingelheim
Drug timelines are a Plus or Pro feature.

22 regulatory and trial events tracked for SPESOLIMAB, covering 2021-06-11 to 2026-06-17. Get the full timeline:

Most recent: Clinical Trial Results: A Study to Test Long-term Treatment With Spesolimab in People With a Skin Condition Disease Called Hidradenitis Suppurativa (HS) Who Took Part in a Previous Study With Spesolimab [Phase 2, Phase 3]

See pricing